Catalyst
Slingshot members are tracking this event:
Ionis Pharmaceuticals (IONS) to submit regulatory application for Inotersen, which treats TTR amyloidosis, to US FDA by end of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IONS | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 06, 2017
Occurred Source:
http://ir.ionispharma.com/news-releases/news-release-details/ionis-announces-submission-new-drug-application-nda-inotersen-us
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ttr Amyloidosis, Inotersen, Fda Review
